TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00776477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel and aspirin
Description: clopidogrel 75mg daily and aspirin 100mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg daily
Study: NCT02060539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity XR
Study: NCT04553289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercising into pain
Description: the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercising with no/slight pain
Description: the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
Study: NCT00542776

Intervention type: OTHER
Intervention: blood draw
Description: drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)

Intervention type: OTHER
Intervention: blood draw
Description: drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
Study: NCT02133222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT03570567

Intervention type: DEVICE
Group type: OTHER
Intervention: Piranha Treatment
Description: The piranha device is used with an endoscope to breakup/dislodge the food bolus.
Study: NCT04288102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline containing 1% Human serum albumin（solution without UC-MSCs）
Description: 3 does of placebo（intravenously at Day 0, Day 3, Day 6）
Study: NCT04137744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AXILLARY REVERSE MAPPING
Description: subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AXILLARY REVERSE MAPPING
Description: subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
Study: NCT01582841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSI screening test
Description: All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
Study: NCT02783027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepTrackTXT2
Description: Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
Study: NCT03390764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4:1 closure group
Description: In this arm the incisions are closed by the 4:1-technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RTL plus 4:1 closure group
Description: In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
Study: NCT02703181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban (GSK557296)
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
Study: NCT02858466

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan
Study: NCT00521365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 600mg
Description: 300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day.
Study: NCT01929889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
Study: NCT03034369

Intervention type: OTHER
Intervention: Access to Care
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.

Intervention type: OTHER
Intervention: Depression Screening
Description: Analysis of health care claims data for depression screenings at baseline and 12 months.

Intervention type: OTHER
Intervention: Patient-Provider Relationship
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.

Intervention type: OTHER
Intervention: Patient-Clinic Interactions
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.

Intervention type: OTHER
Intervention: Stigma
Description: Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.

Intervention type: OTHER
Intervention: Provider Continuity
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.

Intervention type: OTHER
Intervention: Symptom Severity
Description: Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.

Intervention type: OTHER
Intervention: Diagnoses
Description: Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.

Intervention type: OTHER
Intervention: Social support
Description: Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.

Intervention type: OTHER
Intervention: Preventive Screening
Description: Analysis of health care claims data for preventive screenings at baseline and 12 months.

Intervention type: OTHER
Intervention: Inpatient Hospitalization Utilization
Description: Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.

Intervention type: OTHER
Intervention: Inpatient Readmissions
Description: Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.

Intervention type: OTHER
Intervention: Post-Admission follow-up
Description: Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
Study: NCT06380062

Intervention type: OTHER
Intervention: Plasma concentration of choline
Description: The exposure in this observational study is plasma concentrations of choline

Intervention type: OTHER
Intervention: Plasma concentration of choline
Description: The exposure in this observational study is plasma concentrations of choline
Study: NCT02776293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Study: NCT01694693

Intervention type: DRUG
Intervention: Orencia
Description: No Intervention
Study: NCT03922880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
Study: NCT03627832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study: NCT04391257

Intervention type: DEVICE
Group type: OTHER
Intervention: geko™
Description: Assess if cardiac pacemakers detect geko™ electrical output pulse.
Study: NCT02217748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Study: NCT03759925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Support
Description: Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
Study: NCT03673891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Life Flow
Description: LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
Study: NCT01166256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 \>92% or PaO2 \>65 mmHg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula system
Description: High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 \>92% or PaO2 \>65 mmHg.
Study: NCT02683109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of tiotropium + olodaterol
Description: Fixed Dose Combination of tiotropium + olodaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Study: NCT02830568

Intervention type: PROCEDURE
Intervention: open donor nephrectomy
Description: open donor nephrectomy

Intervention type: PROCEDURE
Intervention: standard and hand-assisted laparoscopic donor nephrectomy
Description: standard and hand-assisted laparoscopic donor nephrectomy

Intervention type: PROCEDURE
Intervention: laparoscopic robotic-assisted nephrectomy
Description: laparoscopic robotic-assisted nephrectomy
Study: NCT02987699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
Study: NCT03019848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01607164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Mood Project Website
Description: Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
Study: NCT01884883

Intervention type: DEVICE
Group type: OTHER
Intervention: PROTEOR Internal unicompartmental knee brace
Study: NCT04137198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
Study: NCT03350386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaprozin
Description: Repeated administration
Study: NCT03458377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational telephone call
Description: Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
Study: NCT03290430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Counseling
Description: 8 sessions over 4 weeks. Lasting 1-2 hours each

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Counseling
Description: 8 in person sessions over 4 weeks. Lasting 30-45 minutes each

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: 8 phone sessions over 4 weeks. Lasting 30-45 minutes each
Study: NCT02703181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK557296
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
Study: NCT04238949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker added to diabetes team
Description: A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
Study: NCT04490759

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT02330705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: Women will be given HCG before IUI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: Women will be given HCG before IUI
Study: NCT03290430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Counseling
Description: 8 video call sessions over 4 weeks. Lasting 30-45 minutes each

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting support
Description: Texts with smoking cessation support throughout the program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting support
Description: Texts with smoking cessation support throughout the program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting support
Description: Texts with smoking cessation support throughout the program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting support
Description: Texts with smoking cessation support throughout the program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
Study: NCT02330705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: Women will be given HCG before IUI
Study: NCT00841217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW501516
Description: 2.5mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Study: NCT00859729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection
Study: NCT03912363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotating fluids protocol
Description: IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin infusion protocol
Description: Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose
Study: NCT02626988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a biodiverse diet
Description: Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
Study: NCT04200001

Intervention type: OTHER
Intervention: Quality of life
Description: The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ-BR23~* EORTC SHQ-C22~* CUPIDON 2 specific questionnaire
Study: NCT04999618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haemoblock
Description: Delivering with transdermal patches

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivering with transdermal patches
Study: NCT00772330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Drainage Device
Description: Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye